Navigation Links
Scientists Identify New Possible 'biomarker' for Pancreatic Cancer

University of Cincinnati researchers have identified a specific cell receptor, which they say is a potential biological target for pancreatic cancer.

Led by Dr. Andrew Lowy and Dr. Susan Waltz, the study found that the RON receptor tyrosine kinase was "over-expressed" in pancreatic cancer cells, suggesting that the receptor may also contribute to the disease's development.

The researchers say that their findings, published in the journal Cancer Research, may help scientists better understand and treat the disease that kills more than 33,000 people each year.

Published in the journal Cancer Research, this is the first study to establish the link between the RON receptor and pancreatic cancer. The report also tells that receptor tyrosine kinases are proteins on the cell surface used to activate specific body functions like cell growth and migration.

"A normal pancreas has very low levels of RON, but our study showed that as tumours progress, so does the level of RON expression in the pancreas cells -- and those over expressed levels were maintained in 'metastases,' the areas that the tumours spread to," explains Waltz, Associate Professor and Director of the Oncology Research Program, Surgery Department, Cincinnati University.

During the study, the researchers noted that the RON receptor was active in 93 per cent of pancreatic intraepithelial neoplasia, an early form of pancreatic duct cancer. They also observed that the receptor was present in 79 per cent of primary pancreatic cancers, and 83 per cent of metastatic cancers.

Waltz believes that the RON receptor's signalling pathways may be a key factor contributing to pancreatic cancer progression, and that it may give drug developers a new target for RON directed therapies that are more effective in treating the deadly disease.

"When cells became invasive, we saw higher levels of RON expression that correlated with the aggressive nature of this disease and cancer metastasis. Clearly, this signaling pathway is associated with pancreatic cancer and merits further investigation," Waltz said.

During the study, the researchers used the protein HGFL to activate the RON receptor.

They observed that though stimulating the RON receptor had no effect on pancreatic cell growth, blocking it with targeted antibodies killed more cancer cells than did the standard treatment drug gemcitabine alone.

"Our findings suggest that combining antibodies that block the RON receptor and the standard chemotherapy drugs might stop progression of pancreatic cancer more effectively. RON could be a promising molecular target for future cancer drug development," says Waltz.

However, the researchers, who had reported in December last year the association between the RON receptor and breast cancer, say that further studies is needed before blockers for the RON receptors may be used for human testing.


'"/>




Related medicine news :

1. Scientists plan human cloning clinic in the United States
2. Scientists found ancient Human Germ Killer
3. Scientists locate key hormone involved in appetite control
4. Scientists open the book of life
5. Scientists review SARS
6. Scientists crack dengue fever puzzle
7. Scientists push to lower hidden sodium in food
8. Indian Scientists Make Wide-Ranging Analysis And Annotation Of X Chromosome
9. Scientists have found effective brain regions for deep brain stimulation for Parkinson’s
10. Scientists reveal the secrets of sarcasm
11. Scientists Unveil Mechanism Behind Resistance to Severe Malaria
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/6/2016)... ... December 06, 2016 , ... It can be argued that people these days ... members as they do for their human friends and family. As pets have ... highest quality and most innovative pet products has also increased. , For ...
(Date:12/6/2016)... ... December 06, 2016 , ... The Behavioral Health Center ... recognizing the organization as a top behavioral service provider in the country. The ... quality, staff satisfaction and qualifications, and consumer satisfaction. These areas are measured via ...
(Date:12/6/2016)... ... December 06, 2016 , ... Gateway Analytical, one of ... particle counting and sizing services for USP 788 and 789 particulate standards compliance. ... as a response to the needs of pharmaceutical and medical device manufacturers, who ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... the much-anticipated HydroFX for Water®. This first-of-its-kind water-soluble powder supplement has a ... world’s most powerful antioxidants, molecular hydrogen, HydroFX for Water transforms every day ...
(Date:12/6/2016)... Vancouver, B.C., Canada (PRWEB) , ... December 06, ... ... Consultants (STC) announce the availability of the newly updated International Audit Protocol Consortium ... world use IAPC EHS audit protocols to understand the scope of their EHS ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... N.J. , Dec. 5, 2016  Daiichi ... preliminary safety and efficacy data from a phase ... MDM2 inhibitor, suggesting that DS-3032 may be a ... myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). ... the phase 1 study of DS-3032 were presented in ...
(Date:12/5/2016)... -- BD (Becton, Dickinson and Company) (NYSE: BDX ... an enhanced technology platform designed with the ability to ... Pyxis™ and Alaris™ systems, at this year,s American ... being held in Las Vegas ... that approximately 68 percent of medication errors occur during ...
(Date:12/5/2016)... , Dec. 5, 2016 Eisai Inc. ... at the 2016 Annual Meeting of the American Epilepsy ... CIII, is indicated as an adjunctive therapy for the ... secondarily generalized seizures and primary generalized tonic-clonic seizures (PGTC) ... age and older. Please see Important Safety Information for ...
Breaking Medicine Technology: